eligibility_summary
Eligible: children 3–16 with definite SDNS in relapse, steroid‑dependent (≤0.3 mg/kg/day), ≥6 months steroids, able to swallow tablets, eGFR ≥90, guardian understanding and written consent. Exclude: secondary/hereditary NS, ANCA+ or low C3, no response after 14 days full‑dose prednisone, allergy to MMF/rituximab, other trials/refusal, HBV/HCV or abnormal LFTs, cytopenias, recent pancreatitis/GI ulcers/bleed, immunodeficiency/active infections (e.g., TB/CMV), serious illness, cancer <5 y, major CV disease, or IV‑antibiotic infections.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Randomized Phase 2 trial in children with steroid-dependent nephrotic syndrome comparing two immunosuppressants: 1) Rituximab (IV chimeric anti-CD20 monoclonal antibody). Mechanism: binds CD20 on B lymphocytes, causing B-cell depletion via complement- and antibody-dependent cytotoxicity and apoptosis, reducing autoantibody production and B–T cell costimulation, indirectly stabilizes podocyte injury by dampening humoral immunity. Targets: CD20+ B cells, humoral immune pathway. 2) Mycophenolate mofetil (oral prodrug of mycophenolic acid, antimetabolite immunosuppressant). Mechanism: selectively inhibits inosine monophosphate dehydrogenase (IMPDH), blocking de novo guanine synthesis and proliferation of activated T and B cells, lowering antibody formation and T-cell responses. Targets: proliferating T and B lymphocytes, IMPDH-mediated nucleotide synthesis pathway.